Literature DB >> 31949946

Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.

Seung Yoon Yang1, Jae Hyun Kang1, Ho Seung Kim1, Yoon Dae Han1, Byung Soh Min1, Kang Young Lee1.   

Abstract

Peritoneal carcinomatosis (PC) was previously considered an incurable disease with a poor survival outcome. As our understanding of its biology evolved, the paradigm of the management of PC from colorectal cancer (CRC) has changed, including the combination of macroscopic disease control, cytoreductive surgery (CRS), maximal regional chemotherapy to treat residual microscopic disease, and hyperthermic intraperitoneal chemotherapy (HIPEC). As with many surgical innovations, CRS with HIPEC has evolved faster than data to support it, leaving many skeptics and critics. This review highlights the recent evidence of current practice and outcome of CRS with HIPEC. Furthermore, it also summarizes the ongoing clinical trials and potential future progress of this treatment modality. 2019 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Colorectal cancer (CRC); cytoreductive surgery (CRS); hyperthermic intraperitoneal chemotherapy (HIPEC); peritoneal carcinomatosis (PC)

Year:  2019        PMID： 31949946      PMCID： PMC6955007          DOI： 10.21037/jgo.2019.01.36

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  99 in total

1.  Studies on abdominal organ perfusion for cancer chemotherapy.

Authors:  W W SHINGLETON; J W REEVES; R A KEPPEL; S MAHALEY; I M TAYLOR
Journal:  Ann Surg       Date:  1960-05       Impact factor: 12.969

Review 2.  Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature.

Authors:  George Dranitsaris; Mary Johnston; Susan Poirier; Trudi Schueller; Debbie Milliken; Esther Green; Brent Zanke
Journal:  J Oncol Pharm Pract       Date:  2005-06       Impact factor: 1.809

Review 3.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

Review 4.  Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality.

Authors:  Terence C Chua; Tristan D Yan; Akshat Saxena; David L Morris
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

5.  Metastatic pattern in colorectal cancer is strongly influenced by histological subtype.

Authors:  N Hugen; C J H van de Velde; J H W de Wilt; I D Nagtegaal
Journal:  Ann Oncol       Date:  2014-02-06       Impact factor: 32.976

6.  Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique.

Authors:  A D Stephens; R Alderman; D Chang; G D Edwards; J Esquivel; G Sebbag; M A Steves; P H Sugarbaker
Journal:  Ann Surg Oncol       Date:  1999-12       Impact factor: 5.344

7.  Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: Two pathogenetic types based study.

Authors:  Roman Yarema; Taras Fetsych; Natalya Volodko; Myron Оhorchak; Orest Petronchak; Roman Huley; Yuriy Mylyan; Olivier Glehen
Journal:  J Surg Oncol       Date:  2018-05-14       Impact factor: 3.454

8.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.

Authors:  Dominique Elias; François Gilly; Florent Boutitie; François Quenet; Jean-Marc Bereder; Baudouin Mansvelt; Gérard Lorimier; Pierre Dubè; Olivier Glehen
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

9.  Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.

Authors:  Angela Casado-Adam; Robert Alderman; O Anthony Stuart; David Chang; Paul H Sugarbaker
Journal:  Int J Surg Oncol       Date:  2011-10-16

10.  HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma.

Authors:  A Arjona-Sánchez; P Barrios; E Boldo-Roda; B Camps; J Carrasco-Campos; V Concepción Martín; A García-Fadrique; A Gutiérrez-Calvo; R Morales; G Ortega-Pérez; E Pérez-Viejo; A Prada-Villaverde; J Torres-Melero; E Vicente; P Villarejo-Campos; J M Sánchez-Hidalgo; A Casado-Adam; Ruben García-Martin; Manuel Medina; T Caro; C Villar; Enrique Aranda; M T Cano-Osuna; C Díaz-López; E Torres-Tordera; F J Briceño-Delgado; S Rufián-Peña
Journal:  BMC Cancer       Date:  2018-02-13       Impact factor: 4.430
View more
  2 in total

1.  The role of hyperthermic intraperitoneal chemotherapy in the treatment of spontaneously ruptured hepatocellular carcinoma: a pilot study.

Authors:  Shiye Ruan; Ning Shi; Zhihong Chen; Hongwei Han; Hanyue Wang; Liang Jin; Yiping Zou; Yuanpeng Zhang; Min Yu; Haosheng Jin
Journal:  Ann Transl Med       Date:  2020-09

Review 2.  Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses.

Authors:  Niloy R Datta; H Petra Kok; Hans Crezee; Udo S Gaipl; Stephan Bodis
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.